CD266 TNFRSF12A (tumor necrosis factor receptor superfamily member 12A), FN14, Fn14, TWEAK-R, TWEAKR
Molecule TypeAntigen ExpressionMolecular Weight
Min / Max
Non-lineage Restricted Molecule
Type 1 glycoprotein
Epithelial Cell
Endothelial Cell
Keratinocyte
Placenta
Heart
Lung
Kidney
Muscle, Smooth
Brain
Brain
Tumor Cell
Pancreas
14 / 14

Expression

CD266 is expressed on vascular endothelial and epithelial cells and keratinocyte.  CD266 mRNA expression has been detected in a variety of adult tissues with high expression is in the heart, lung, placenta, kidney, cultured aorta, vascular endothelial cells and smooth muscle.  Expression is low in normal brain and liver but is elevated in human liver and brain tumors and carcinoma specimens.  Overexpression of CD266 has been observed in pancreatic tumors.



Structure
MOLECULAR FAMILY NAME: Belongs to the tumor necrosis factor receptor family.

CD266 is a single-pass type-1 102 aa glycoprotein.  It contains a 27 aa N-terminal single sequence which is cleaved to form the 102 aa mature protein, a 53 aa extracellular which contains an incomplete TNFR cysteine domain, a 21 aa transmembrane domain and 29 aa cytoplasmic domain containing a TRAF-binding site (TRAF1, 2, 3 and 5) which are known to bind the site and flanked by 2 threonines which are the only potential phosphorylation sites.  CD266 is leucine-rich (17%) and has 8 cysteines but does not have any asparagines or tyrosines.

MOLECULAR MASS

POST-TRANSCRIPTIONAL MODIFICATION

Alternative splicing yields 2 different isoforms.

POST-TRANSLATIONAL MODIFICATION: No information.

Ligands
LIGANDS AND MOLECULE ASSOCIATED WITH CD266

CD266 binds a tumor necrosis factor-like weak inducer of apoptosis CD255 (TWEAK).

Function
CD266 signaling appears to mediate CD255, the fully functional TWEAK receptor, which induces proliferation and migration of endothelial cells and pro-inflammatory activity of CD255 and may modulate cellular adhesion to matrix proteins.  There is no evidence that CD266 is involved in the apoptotic properties of CD255.  Both CD255 and CD266 are co-expressed in several cell types and tissues enabling autocrine signaling.  Expression of CD266 is upregulated in response to physical damage and certain cytokines and this would be expected to enhance CD255 mediated effects.  CD266 plays a role in regulating apoptosis and proliferation in some cell types.

BIOCHEMICAL ACTIVITY: No information.

DISEASE RELEVANCE AND FUNCTION OF CD266 IN INTACT ANIMAL

CD288 may play a role in hepatocyte growth control and liver neoplasia.

Comments
MOLECULAR INTERACTIONS-
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD266: No information.

SUBSTRATES: No information.

ENZYMES WHICH MODIFY CD266: No information.



Database accession numbers
AnimalPIRSWISSPROTEMGBL/GENBANK
 
HumanEntrezgene51330Q9NP84
Antibodies

Revised June 25, 2008


Contact us: Webmaster |  509-335-9515 | Accessibility | Copyright | Policies
College of Veterinary Medicine Washington State University, Pullman, WA, 99164-7010 USA
Copyright 1995-2003 Washington State University